Results 121 to 130 of about 19,665 (228)

Treatment of refractory juvenile idiopathic arthritis via pulse therapy using methylprednisolone and cyclophosphamide

open access: yesSão Paulo Medical Journal
CONTEXT: Patients with refractory juvenile idiopathic arthritis can benefit from aggressive therapy. CASE REPORT: We followed the clinical course of 4 patients (2 male, 2 female) aged 9.1-17.8 years (mean of 14.5 years) with polyarticular onset of ...
Tania Caroline Monteiro de Castro   +3 more
doaj   +1 more source

Systemic Juvenile Idiopathic Arthritis Complicated by Mesengioproliferative Glomerulonephritis

open access: yesTurkish Journal of Nephrology, 2019
Juvenile idiopathic arthritis (JIA), one of the most common rheumatic diseases of childhood, is characterized by chronic synovitis and other organ dysfunctions.
İsmail DURSUN   +5 more
doaj  

Continued Nintedanib Treatment in Children and Adolescents With Fibrosing ILDs: Data From InPedILD‐ON

open access: yesPediatric Pulmonology, Volume 61, Issue 6, June 2026.
ABSTRACT Background In the InPedILD trial, nintedanib had an acceptable safety profile in children and adolescents (aged 6−17 years) with fibrosing ILDs. The open‐label extension of the InPedILD trial, InPedILD‐ON, is assessing the longer‐term safety of nintedanib in these patients. Methods Patients who completed the InPedILD trial on treatment and had
Robin Deterding   +14 more
wiley   +1 more source

Original paper Prevalence of HLA-B27 antigen in patients with juvenile idiopathic arthritis

open access: yes, 2015
Introduction: Human leukocyte antigen B27 (HLA-B27) is considered as a risk factor for development of juvenile idiopathic arthritis (JIA). The aim of this study was to analyse the prevalence of HLA-B27 antigen in JIA categories and its influence on ...
Jerzy Chudek   +3 more
core   +1 more source

Age‐Dependent Differences in Canakinumab Safety: A Comprehensive Pharmacovigilance Analysis Using the FAERS Database

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT While the efficacy of canakinumab, an anti‐interleukin‐1β monoclonal antibody, is well‐established, its safety profile, particularly across different age groups, remains inadequately explored. Using the FDA Adverse Event Reporting System (FAERS) database, this study evaluated postmarketing safety by analyzing adverse event (AE) reports from ...
Youyang Wang   +3 more
wiley   +1 more source

Tubulointerstitial nephritis and uveitis syndrome in children: What to keep an eye on

open access: yesActa Ophthalmologica, Volume 104, Issue 4, Page e443-e452, June 2026.
Abstract Purpose The purpose of this study was to determine the disease course in patients with tubulointerstitial nephritis and uveitis (TINU) syndrome, focusing on long‐term outcome and the incidence of complications such as chronic kidney disease (CKD).
Jytte Hendrikse   +4 more
wiley   +1 more source

Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis: Refractory Arthritis, Recurrent Macrophage Activation Syndrome and Chronic Lung Disease

open access: yes, 2021
Systemic juvenile idiopathic arthritis is a distinct and heterogeneous disease presently classified under the umbrella of juvenile idiopathic arthritis, with some patients following a monophasic remitting course, whereas others have persistent disease ...
Towe, Christopher   +4 more
core  

Predictive Factors for Relapse in Still's Disease: A Retrospective Cohort Study of Clinical and Laboratory Biomarkers

open access: yesClinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT This retrospective cohort study aimed to identify clinical and laboratory predictors of relapse in patients with Still's disease. A total of 94 patients diagnosed by Yamaguchi or Fautrel criteria across two rheumatology centers between 2012 and 2024 were evaluated, of whom 87 were eligible for analysis.
İbrahim Yahya Çakır   +12 more
wiley   +1 more source

Current Review of Systemic Juvenile Idiopathic Arthritis: What Do Paediatricians Need to Know? [PDF]

open access: yes
Systemic juvenile idiopathic arthritis is classified as an autoimmune entity and a subtype of juvenile idiopathic arthritis, although it has many features of autoinflammatory-type of diseases.
Albaker, Asma R.
core   +1 more source

Case report: Suspected transfusion-related acute lung injury type II in a child with refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome

open access: yesFrontiers in Pediatrics
IntroductionTransfusion-related acute lung injury is a rare but potentially fatal complication, which may appear during or post-transfusion of blood products.
Alenka Gagro   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy